Gregory Koo
General Practice · Lexington, KYNPI 1205895943
Payments from drug & device makers
Across 87 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$243
- GSK$175
- Lilly USA, LLC$173
- AbbVie$117
- AstraZeneca$100
- Novo Nordisk$97
- plus $439 from 15 others
What the payments were for
- Food & beverage$1,33399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $243 |
| GSK | 12 | $175 |
| Lilly USA, LLC | 12 | $173 |
| AbbVie | 6 | $117 |
| AstraZeneca | 7 | $100 |
| Novo Nordisk | 6 | $97 |
| Pfizer | 6 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $51 |
| Amgen | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Johnson & Johnson | 2 | $31 |
| Mylan Specialty L.p. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Novartis | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$1,345 in reported general payments places this provider in the 85th percentile of 1,155 general practice providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $139,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $55,600 |
| EliquisApixaban | 47 | $36,942 |
| JardianceEmpagliflozin | 41 | $35,731 |
| TrulicityDulaglutide | 28 | $31,089 |
| MounjaroTirzepatide | 24 | $23,336 |
| Omega-3 Acid Ethyl Esters | 496 | $18,948 |
| LinzessLinaclotide | 12 | $12,264 |
| FarxigaDapagliflozin Propanediol | 13 | $11,411 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $8,597 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,167 |
| VascepaIcosapent Ethyl | 17 | $7,269 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 126 | $4,126 |
| Celecoxib | 64 | $3,287 |
| Potassium Chloride | 230 | $2,749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $97 | $139,052133 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $175 | $63,767103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $173 | $54,42552 claims |
| PfizerEliquis | $93 | $36,94247 claims |
| Boehringer IngelheimJardiance | $19 | $35,73141 claims |
| AbbVieLinzess | $117 | $12,26412 claims |
| AstraZenecaFarxiga | $100 | $11,41113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,155 general practice providers in Kentucky.
Other general practice in Lexington
- Stephen SterlitzLexington$263K
- William WorkmanLexington$166K
- Ryan GolibersuchLexington$23K
- Joseph ChambersLexington$10K
- Paul KoshgerianLexington$8K
- Morgan ChambersLexington$7K
- John MullinsLexington$6K
- William CarteeLexington$5K
- William DiamondLexington$3K
- Teresa LyonLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.